Imagine the monies that will be saved from insurance companies not needing to move from 1st line treatment to 2nd line treatment and to 3rd....
All they want to see is progress, like all patients when they are given treatment ....and if just 15% !! can be treated properly....(with PS Targeting combo treatment) then that % will increase and whomever owns PS Targeting at the time...will begin to see waves of transition of market caps redirected into PS Targeting
WHO will want to be part of that? It seems Merck has become more excited than AstraZeneca and I am sure there are others positioning themselves all along
Let's go Calico....and Mr Sergey Brin, time is a running out : )
Market Data 
Markets 
AI
